| 000 | 00904 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250518014110.0 | ||
| 264 | 0 | _c20191115 | |
| 008 | 201911s 0 0 eng d | ||
| 022 | _a2168-6157 | ||
| 024 | 7 |
_a10.1001/jamaneurol.2018.4150 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCharles, James A | |
| 245 | 0 | 0 |
_aConsideration of Costs and Open-label Studies of Erenumab. _h[electronic resource] |
| 260 |
_bJAMA neurology _c02 2019 |
||
| 300 |
_a236 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 | _aAntibodies, Monoclonal |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aCalcitonin Gene-Related Peptide Receptor Antagonists |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMigraine Disorders |
| 773 | 0 |
_tJAMA neurology _gvol. 76 _gno. 2 _gp. 236 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/jamaneurol.2018.4150 _zAvailable from publisher's website |
| 999 |
_c29188286 _d29188286 |
||